Cellectis’ Cema-cel Achieves 58.3% MRD Negativity, No Severe AEs
Cellectis-highlighted interim futility analysis from Allogene’s pivotal ALPHA3 trial showed 58.3% MRD negativity in the cema-cel arm versus 16.7% in observation, a 41.6% absolute increase. Cema-cel had no CRS, ICANS, GvHD or AEs, treated 10 of 12 patients outpatient, and could earn Cellectis $340M in milestones.
1. Interim Futility Analysis Results
The ALPHA3 trial interim futility analysis of cema-cel in first-line consolidation for large B-cell lymphoma showed 58.3% MRD negativity (7/12) versus 16.7% (2/12) in the observation arm, representing a 41.6% absolute clearance difference that exceeds clinical benchmarks for meaningful benefit.
2. Safety and Tolerability Data
Cema-cel was generally well tolerated with no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease or treatment-related serious adverse events; 10 of 12 patients were managed outpatient after infusion.
3. Milestones and Regulatory Outlook
Allogene anticipates completing study accrual by end-2027, with an interim event-free survival analysis in mid-2027 and a primary analysis in mid-2028; positive results could support a BLA submission and trigger up to $340 million in Cellectis development and sales milestone payments plus royalties.